Pamela L. Kunz, MD, discusses the most recent FDA approval of Lutathera (lutetium [Lu 177] dotatate) for the treatment of patients with gastroenteropancreatic NETs (GEP-NETs), including foregut, midgut, and hindgut tumors.
Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the most recentFDA approval of Lutathera(lutetium [Lu 177] dotatate) for the treatment of patients with gastroenteropancreatic NETs (GEP-NETs), including foregut, midgut, and hindgut tumors.
The agent was approved by the FDA in 2018 for the treatment of patients with somatostatin receptorpositive GEP-NETs. Lutetium 177 is a radiolabeled somatostatin analog, says Kunz. The agent is given to patients by intravenous infusion for 4 doses.
Lutetium 177 represents a new class of therapy across all oncology. Kunz says there is a target on NET cells called the somatostatin receptor, and this receptor is the target for peptides like octreotide. She describes this as a lock and key scenario, where the receptor is the lock while the peptide acts as a key, bringing lutetium 177 along with it.
Pembrolizumab/Trastuzumab/Chemo Enhances Survival in HER2+ Gastric Cancer
May 1st 2024The combination of pembrolizumab, trastuzumab, and chemotherapy showed significant improvement in overall survival vs placebo in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More